MEDVi FDA Warning Letter and $1.8 Billion NYT Profile: The Full Story Behind the Fastest-Growing Telehealth Company in 2026

Last updated Nov 9, 2026

By HealthDataConsortium.org Research Team

FTC Affiliate Disclosure: This article may contain affiliate links. If you enroll through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented.

MEDVi responded publicly to FDA warning letter allegations on April 8. Here’s what the company said, what remains unanswered, and what it means for consumers evaluating the program. Updated April 11, 2026.

In early April 2026, MEDVi — a GLP-1 telehealth startup founded by entrepreneur Matthew Gallagher, reportedly of Los Angeles — became one of the most talked-about companies in American healthcare almost overnight. A New York Times profile published April 2 presented MEDVi as a potential proof-of-concept for Sam Altman’s prediction that artificial intelligence could enable a single founder to build a billion-dollar company. The Times said it was given access to MEDVi’s financials to verify revenue and profits, and MEDVi is projected to reach $1.8 billion in 2026 sales — with only two full-time employees.

The story immediately went viral. Forbes, Inc., PYMNTS, and dozens of other outlets followed with their own coverage. But within 24 hours, a parallel narrative emerged — one centered on regulatory warnings, lawsuits, and questions about MEDVi’s advertising practices — raising important questions that consumers searching for MEDVi information should understand before making enrollment decisions.

This report examines both sides of the MEDVi story using publicly available data, regulatory filings, and verified reporting from multiple sources.

What is MEDVi, where is it based, and how do I log in?

MEDVi is an online telehealth company that sells weight-loss medication. Its homepage also lists peptides and longevity, men’s health and women’s health care. The weight-loss products include compounded semaglutide and tirzepatide, along with brand-name Wegovy, Zepbound and Ozempic. MEDVi, LLC is based in Newark, Delaware, and the website footer gives a street address in that city. The FDA’s February 2026 warning letter is addressed to the same Newark office.

Prescriptions come from licensed clinicians. The homepage says medical treatment is provided by “CareGLP Affiliated P.C.s” and OpenLoop Health, and that MEDVi “is not acting as a pharmacy.” The three partner pharmacies named on the site are Triad Rx in Alabama, RedRock Pharmacy in Utah and Beaker Pharmacy & Compounding in Texas.

MEDVi login and patient portal

The homepage describes the patient portal as the place to “track your progress, check in with your provider, and manage your care.” Use it to reach your account. If you cannot find the sign-in step, email hello@medvi.org or call (323) 690-1564. The same site lists both emails and that phone number as contacts.

Does MEDVi have an app? The site describes the portal, not a mobile app. Ask support whether there is a separate app before you sign up.

This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.

Is MEDVi FDA approved?

No. The compounded semaglutide and tirzepatide that MEDVi sells are not FDA-approved. MEDVi’s own website says its compounded medications “are not FDA approved or evaluated for safety, efficacy, or quality.” The brand-name medicines are approved. MEDVi’s site says “Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss.”

The FDA warning letter to MEDVi, dated February 20, 2026, states: “Compounded drug products are not FDA-approved.” It says MEDVi’s website claims implied the products had been approved, and it quotes two claims from medvi.io: “Same active ingredient as Wegovy® and Ozempic®” and “Same active ingredient as Mounjaro® and Zepbound®.” The letter also says compounded products must meet sections 503A or 503B of the law to be exempt from certain requirements, including new drug approval requirements.

An approval is tied to a specific drug for specific uses. The National Eye Institute reserpine release notes that reserpine was approved in 1955 for high blood pressure, while its 2023 research looked at a different use, an inherited eye disease. For the difference between compounded and approved versions, read compounded vs fda-approved glp-1 drugs.

Is MEDVi legit and reputable?

Yes, MEDVi is a real company that sells weight-loss medication. Many customers say they receive their medication and like their clinicians. Its record is mixed, and the reasons matter before you pay. The Better Business Bureau rates MEDVi F and not accredited, based on 751 complaints, according to Mira’s MEDVi review.

The FDA sent MEDVi, LLC a warning letter dated February 20, 2026, over claims on the medvi.io website. MEDVi’s April 8, 2026 statement says the letter was aimed at an affiliate marketing agency’s website, that MEDVi required the affiliate to remove the material, and that “My company MEDVi has never received a letter from the FDA.” The FDA’s full warning letter is public, so you can read the claims it quotes yourself.

MEDVi also sells QUAD, an erectile dysfunction product. The Drug Discovery & Development review says ads for QUAD ran from a Facebook page under the name “Dr. Robert Whitworth.” That page is among the apparently fabricated physician personas the review describes. For the product itself, see the MEDVi QUAD ED treatment review.

The Growth Story: What the Numbers Actually Show

The core business thesis behind MEDVi is straightforward. Gallagher launched the company in September 2024 with $20,000 in personal capital and used AI tools — including ChatGPT, Claude, and Grok — to build the platform’s website, marketing materials, customer service systems, and analytics dashboards. Rather than building clinical infrastructure, he partnered with CareValidate and OpenLoop Health, which provide licensed physicians, prescription processing, pharmacy fulfillment, and regulatory compliance.

The model allowed MEDVi to focus entirely on customer acquisition, branding, and the digital checkout experience while medical operations were handled by established telehealth infrastructure providers. According to the Times report, MEDVi attracted 300 customers in its first month, surpassed 1,000 in its second, and reached 250,000 by the end of 2025. The company’s current homepage claims over 500,000 patients.

For context, Hims & Hers Health — a publicly traded telehealth company with over 2,400 employees — reported $2.4 billion in 2025 revenue with a 5.5% net profit margin. MEDVi claims a 16.2% net margin on significantly lower revenue but with essentially zero payroll overhead. Whether those margins are sustainable as the company scales and faces increasing regulatory scrutiny remains an open question.

The FDA Warning Letter: What It Says and What It Doesn’t

On February 20, 2026 — six weeks before the Times profile — the FDA sent MEDVi a warning letter (Letter #721455) identifying misbranding violations on the company’s website. According to the publicly available letter, the FDA found that MEDVi’s site language falsely suggested MEDVi itself was the compounder of the semaglutide and tirzepatide products it sold. The agency also flagged claims that implied FDA approval or evaluation of compounded products.

It is important to note several things about this warning letter in context:

First, MEDVi was not the only company warned. In March 2026, the FDA issued warning letters to more than 30 telehealth companies for similar marketing violations related to compounded GLP-1 products. This was an industry-wide enforcement action, not a targeted investigation of MEDVi specifically. According to a STAT News analysis, at least 30% of the warned companies shared clinical affiliations with just four nationwide medical groups.

Second, a warning letter is not a finding of guilt. The FDA’s own Regulatory Procedures Manual describes warning letters as “informal and advisory” communications that convey the agency’s position but do not constitute final enforcement action. Companies receiving warning letters are given the opportunity to correct the identified issues, and many do so successfully.

Third, MEDVi maintains LegitScript certification — an independent compliance verification that requires ongoing monitoring, transparency standards, and adherence to applicable state and federal laws. LegitScript certification is required by major payment processors and advertising platforms including Google, Meta, and TikTok. This certification remains active as of this publication.

The warning letter does, however, raise legitimate questions about MEDVi’s marketing practices and whether the company’s rapid growth outpaced its compliance infrastructure — a concern that applies broadly across the telehealth GLP-1 space in 2026.

The Advertising Practices Question

A Drug Discovery & Development investigation published April 4, 2026 documented additional concerns about MEDVi’s advertising ecosystem. The report identified more than 5,000 active MEDVi-related ads on Meta’s platform at the time of its search (the review also reports the number fell to roughly 2,800 after Business Insider raised the issues), including some running under apparent fictitious personas with fabricated medical titles. MEDVi’s own website says that individuals appearing in advertisements may be actors or models.

This practice exists within a broader industry context. In December 2025, a bipartisan coalition of 35 state attorneys general wrote to Meta expressing concern about AI-generated weight-loss advertising across the platform — not specific to MEDVi, but addressing the same category of advertising. The telehealth GLP-1 advertising landscape has attracted regulatory attention industry-wide.

It should be noted that the use of actors or models in healthcare advertising is not inherently illegal — the critical compliance question is whether such advertising is clearly disclosed and does not make false medical claims. MEDVi does include a disclosure on its website regarding the use of AI-generated and actor portrayals, though critics argue the placement and prominence of such disclosures may be insufficient.

The OpenLoop Health Situation

One of MEDVi’s two primary clinical infrastructure partners, OpenLoop Health, has faced its own set of challenges in early 2026. In January, OpenLoop disclosed a cybersecurity breach in which a threat actor claimed to have accessed records from approximately 1.6 million patients. The company confirmed at least 68,160 affected individuals in Texas and now faces multiple class-action lawsuits related to the breach.

Separately, a class-action complaint filed in November 2025 against OpenLoop and compounding pharmacy Triad Rx alleges that compounded oral tirzepatide tablets sold through the network had “no demonstrated mechanism of absorption or efficacy.” The complaint names MEDVi as one of multiple consumer-facing storefronts in the OpenLoop network.

These are allegations in pending litigation, not proven findings. OpenLoop continues to operate, and the cases have not been resolved. However, consumers considering any telehealth platform that relies on OpenLoop infrastructure should be aware of these ongoing proceedings. For a detailed analysis of what the breach means for patients and what steps to take, see our telehealth data privacy report.

How much does MEDVi cost per month?

Mira’s review, with prices checked September 30, 2026, lists the regular price of compounded semaglutide at $299 every four weeks, and compounded tirzepatide at $299 to $399 every four weeks, after a discounted first month. MEDVi’s pages do not all agree on these figures, and prices and bundles change, so check today’s price directly with the company at checkout.

MEDVi says it bills every 28 days. Mira’s review notes that this comes to 13 charges a year, or about $324 a calendar month at $299. Over 12 four-week months (48 weeks), Mira’s review works out to $3,468 for semaglutide and $3,488 to $4,588 for tirzepatide at the regular price.

Disclosure: Heads up, this page contains affiliate links. We may earn a commission when you buy through these links.

MEDVi says its price stays the same at every dose, and its pages say “Same price, every dose.” Mira notes that MEDVi’s terms say the charge may “fluctuate” with the medication and pharmacy. To see current options, open the Product Page.

Does MEDVi have a membership fee?

For compounded medication, no separate membership fee is listed. The homepage says “Medication is included in the cost of the MEDVi Program” and lists “No hidden fees.” Mira’s review says the main page describes the price as covering the doctor’s review and the medication, with free shipping.

Brand-name Wegovy and Zepbound are different. MEDVi lists a $99 membership plus the medication cost for them. Because the same pages also say “No membership or hidden fees,” get your total in writing before you pay.

What are the most common MEDVi complaints?

The Better Business Bureau lists 751 complaints against MEDVi, and 135 of them went unanswered, according to Mira’s MEDVi review. The most common complaints in 2026 were:

• Being charged after cancelling, or being told there was no record of the cancellation.
• Unexpected renewals. One complainant paid $149 for a first order and then saw a $299.11 charge with no consultation or shipment. MEDVi replied that it bills on a 28-day cycle after a discounted first month.
• Slow or refused refunds.
• Delays and dose problems, including weeks without medication and shipments with the wrong dose or amount.
• Warm shipments and promised discounts that never appeared.

Several proposed class actions have been filed against MEDVi in federal court. E.P. v. Medvi LLC and J.F. v. Medvi LLC, filed in April 2026, allege that MEDVi’s sign-up pages shared users’ email addresses and activity with Google advertising and analytics tools. MEDVi has asked the court to move both into arbitration. Bland v. Medvi, LLC, also filed in April 2026, alleges that MEDVi sent marketing texts to numbers on the National Do Not Call Registry.

What Consumers Actually Experience: Review Data

Consumer review data presents a mixed picture that is consistent with many rapidly-scaling telehealth platforms:

Trustpilot reported, as of September 30, 2026 in Mira’s MEDVi review, a 4.3 out of 5 rating across 14,876 reviews. Many reviewers report positive experiences with medication effectiveness, fast shipping, and the convenience of the telehealth model.

ConsumerAffairs reported, as of September 30, 2026 in Mira’s MEDVi review, a lower 3.3 out of 5 rating across 2,226 reviews. Negative reviews predominantly cite billing confusion related to auto-renewal policies, difficulty obtaining refunds, and customer service delays.

This discrepancy between platforms is not unusual in telehealth. Trustpilot reviews tend to skew toward customers who had positive experiences, while ConsumerAffairs attracts a higher proportion of consumers seeking resolution for complaints. Neither dataset alone tells the complete story.

What are people saying about MEDVi compounded tirzepatide?

Reviews are mixed. Happy customers praise clinicians who answer questions, quick replies, and medication that arrives within a few days. Some long-term customers report steady weight loss. Mira’s review found that 18 of the 20 most recent five-star reviews in its sample came through MEDVi’s own invitations or review links, so weigh those reviews accordingly.

The complaints about tirzepatide are mostly about dose and vial size. Mira’s review, which draws on individual reviews and BBB complaints rather than published policy, reports the following:

• Reviewers describe starting at 2.125 mg, where the Zepbound label starts at 2.5 mg.
• Three reviewers say the highest dose available is about 11.1 mg a week, while the Zepbound label goes to 15 mg. One reviewer was told the maximum is 12 mg.
• Several reviewers say their vial ran 20 to 40 units short of four doses. Compounded shots are measured in syringe units, and 100 units is 1 mL.
• Reviewers report vitamin B12 or B6 added to their medication. MEDVi says its medications carry “full ingredient labeling on the packaging.”
• MEDVi told the BBB that providers “cannot prescribe higher doses” without documentation of a previous dose.

In March 2026, Eli Lilly warned against compounding tirzepatide with vitamin B-12, as reported in the Drug Discovery & Development review. MEDVi’s homepage says “MEDVi patients typically result in 1-2 lbs per week weight loss after 4 weeks, involving a healthy diet and exercise changes.”

The Broader Compounded GLP-1 Landscape in 2026

The MEDVi story cannot be fully understood without recognizing the massive regulatory uncertainty surrounding the entire compounded GLP-1 market in 2026. The FDA has signaled increasing enforcement against telehealth companies marketing compounded versions of semaglutide and tirzepatide, particularly as drug shortages that initially justified expanded compounding have begun to resolve for some formulations. For consumers specifically evaluating oral versus injectable GLP-1 options, the absorption science behind different delivery formats is an important factor.

Compounded medications — including those available through MEDVi — are not FDA-approved as finished products. MEDVi discloses this on its website, noting that compounded GLP-1s are produced in FDA-regulated facilities but have not been individually evaluated for safety, efficacy, or quality. This distinction is critical for consumer understanding and applies equally to every compounded GLP-1 provider, not just MEDVi.

Consumers evaluating any telehealth GLP-1 program — whether MEDVi, Hims, Ro, Henry Meds, or others — should verify the platform’s current regulatory status, medication sourcing, and pharmacy partnerships before proceeding. The regulatory environment is evolving rapidly, and what was compliant six months ago may not remain so.

MEDVi Responds: The Company’s Official Statement

On April 8, 2026, MEDVi issued a public statement, with an additional section from founder Matthew Gallagher, addressing the wave of coverage that followed the New York Times profile. The statement, characterized by the company as a response to “external speculation,” focused primarily on the FDA warning letter and the advertising practices controversy. It’s worth examining what the statement says directly.

On the FDA warning letter, Gallagher drew a distinction between two domain names: medvi.io — the URL cited in the FDA’s warning letter — and medvi.org, which the company describes as its primary domain. According to the statement, the medvi.io domain was operated by an affiliate marketing agency, not by MEDVi directly. The company’s position is that the warning was directed at an affiliate whose website contained outdated copy, and that MEDVi required the affiliate to remove the flagged materials immediately. MEDVi’s statement reads: “My company MEDVi has never received a letter from the FDA.”

The company says it required the affiliate to remove the flagged materials and understands the affiliate responded directly to the FDA. This is a meaningful distinction if accurate — affiliate-operated domains creating compliance issues is a documented pattern across the broader GLP-1 telehealth industry, not unique to MEDVi.

On the advertising controversy, Gallagher acknowledged that MEDVi “recently became aware” of advertisements featuring what appeared to be AI-generated medical practitioners and stated the company has since updated its marketing practices to explicitly prohibit this type of advertising. MEDVi also reiterated its commitment to operating transparently and stated that course corrections have been made at each stage of the company’s growth.

For consumers, the practical takeaway from the statement is that MEDVi continues to hold its LegitScript certification, maintains licensed clinical partnerships, and has taken active steps to address the advertising concerns raised publicly. The company did not announce any service disruptions, changes to medication sourcing, or modifications to its clinical partnerships.

What the Response Addresses — and What Remains Open

MEDVi’s statement is a reasonable starting point for consumers trying to evaluate the company’s position. A fair reading of the available public record, however, identifies a few specific questions the statement didn’t directly answer — and that are worth knowing about if you’re considering enrolling.

The most specific open question involves the medvi.org/welcome page. At the time the FDA warning was issued in February 2026, archived versions of medvi.org — the domain MEDVi identifies as its own primary address — reportedly featured Medvi-branded drug imagery similar to what the FDA flagged on medvi.io. The company’s statement addressed only the medvi.io affiliate domain, not what appeared on medvi.org during the same period. As of this publication, that specific question hasn’t been publicly answered.

A second open area involves compounded oral tirzepatide. Some MEDVi welcome pages have featured this product. It’s worth noting — as this report has covered previously — that compounded oral tirzepatide currently has no published clinical evidence of absorption or weight loss efficacy. Injectable tirzepatide (the active ingredient in FDA-approved Zepbound) has an established evidence base; the oral compounded version does not. This applies to any telehealth provider offering this format, not MEDVi specifically, but it’s a relevant consideration for anyone evaluating this particular product option.

On the advertising issue, the company said it “recently became aware” of fake-doctor ad accounts — though many of those accounts were deleted or altered within hours of media inquiries, raising questions about the timeline. The company hasn’t clarified this publicly.

None of these open questions constitute findings of wrongdoing. They are exactly what they are: questions that haven’t been publicly answered yet. The appropriate consumer posture is the same one this report has consistently recommended — verify before you enroll, check current regulatory status, and review all terms and disclosures directly on the platform.

What are the pros and cons of using MEDVi?

Here is what MEDVi and its customers point to, set against the record.

How do I cancel MEDVi and get a refund?

Mira’s review quotes MEDVi’s refund policy as saying you should cancel at least 72 hours before your next billing date, by emailing hello@medvi.org or through the patient portal chat, or you will be charged again. Mira advises cancelling in writing and keeping the confirmation.

The policy lists these cases:

• A full refund within 72 hours of signing up, if you have not received any services.
• A refund if a clinician disqualifies you for medical reasons.
• No refund on monthly plans for the month in which you cancel or any earlier month.
• Prepaid plans refunded for each month in which no medication shipped.

The same policy also says, apart from cancellation due to medical disqualification, “IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES.” Read literally, that would cancel the 72-hour and prepaid refunds above. MEDVi’s consent form says “There are no refunds or exchanges,” and asks you to certify, “I will not dispute the payments with my credit card company.” MEDVi has also told the BBB that “recurring charges may process regardless of whether a refill intake has been completed.”

Ask for the refund terms in writing before you pay. If you are charged after cancelling, contact MEDVi first and keep your records. Your card issuer can explain your options.

Before you order: what to get in writing from MEDVi

• Your second charge, its date, and whether billing is monthly or every 28 days.
• Whether the price is the same at every dose, and the highest dose MEDVi will prescribe.
• Your dose in milligrams for each level, and the strength of the vial.
• Which pharmacy will make your medication.
• Whether a prepaid plan renews automatically, and at what price.
• How to cancel, and written confirmation that you did.

Disclosure: Heads up, this page contains affiliate links. We may earn a commission when you buy through these links.

Start with the Product Page for current program details, then send these questions to hello@medvi.org before you enter payment information.

Fair Assessment: Where Things Stand as of April 11, 2026

The MEDVi picture has filled in considerably since this report was first published on April 4. The company’s response — combined with independent reporting from multiple outlets — gives a clearer, if still incomplete, view of what MEDVi is and where it stands today.

On the credit side: MEDVi continues to operate with LegitScript certification, verified clinical partnerships, and hundreds of thousands of customers — many of whom report straightforward, positive experiences. Gallagher’s decision to respond publicly rather than go silent is notable. The affiliate domain defense on the FDA warning letter is a factual distinction that deserves fair treatment, even as surrounding questions remain open. And the company’s stated commitment to prohibit AI-generated fake-doctor advertising going forward, if enforced, is the right move for consumers and the industry.

On the open side: the specific question of what appeared on MEDVi’s own primary domain during the enforcement window remains unresolved. The oral tirzepatide evidence gap is a real consumer consideration that applies industry-wide. The litigation involving OpenLoop Health continues without resolution. And several questions raised by independent reporters went unanswered in the company’s official statement.

The standard here isn’t perfection. Every major telehealth platform operating in the compounded GLP-1 space in 2026 has navigated some version of the regulatory complexity MEDVi is facing. The standard is whether the platform delivers what it promises, operates with integrity, and handles compliance problems when they surface. On that measure, MEDVi has taken visible corrective steps — and several key questions remain open. Both things are true.

For consumers who have already enrolled and are satisfied with their care, there’s no current finding that would suggest an immediate need to change course. For consumers actively evaluating whether to enroll, the honest recommendation is the same as it’s always been for any telehealth platform: do your homework, consult your personal healthcare provider, and verify current program details directly before committing.

If you want to review MEDVi’s current program — including pricing, medication options, and enrollment process — the details are available directly through the platform. View current MEDVi program details and pricing.

Consumers deserve access to complete, balanced information when making healthcare decisions. For a step-by-step framework for evaluating any telehealth platform’s credentials before enrolling, see our consumer verification guide.

Anyone considering a GLP-1 telehealth program should consult with their personal healthcare provider, verify the current regulatory status of any platform they’re evaluating, and review all terms, policies, and disclosures before enrolling.

This report was compiled from publicly available regulatory filings, verified news reporting, consumer review platforms, and company disclosures. HealthDataConsortium.org is committed to data-driven health reporting and does not provide medical advice. Individual results with any weight management program vary. Always consult a licensed healthcare professional before starting any medication.

HealthDataConsortium.org Editorial Team | Published April 4, 2026 | Updated April 11, 2026

*These statements have not been evaluated by the Food and Drug Administration. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.